Trial Site Detail

 

Drug:
AUY922
Trial:
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.
Conditions: Solid Tumors
Trial Status:
Ongoing, but not recruiting

 

Medical College of Georgia

     
Augusta , GA 30912
USA

 

Principal Investigator:
Thomas Samuel, M.D.
Contact:
706-721-2505 tsamuel@mcg.edu
Activation Status of this Site:
Closed
Notes about this Site:
Medical College of Georgia Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.